ACAD
ACADIA Pharmaceuticals Inc.
ACAD's fundamentals are mixed, but it looks cheap: trading at 8.6x earnings, about half its usual 16x. Analysts expect strong earnings growth, though they disagree widely on how much.
ACAD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
ACAD's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACAD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8.6x | $18.14 | — |
| Cheap | 9.8x | $20.70 | +14% |
| Fair | 16x | $33.30 | +84% |
| Forward | 17x | $18.14 | — |
| Expensive | 23x | $47.72 | +163% |
Historical ranges are pointers, not guarantees.
ACAD's PE is in its cheap range at 8.6x. On analysts' estimates for next year's earnings, today's price would be 17x, in its fair range.
ACAD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ACAD, with profitability improving. However, they disagree widely on these estimates.
ACAD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.05 | -50% |
| Q3 2026 | $2.12 | +37% |
| Q2 2026 | $2.23 | +68% |
| Q1 2026 | $2.21 | +61% |
| Q4 2025 | $2.30 | +69% |
| Q3 2025 | $1.55 | +99% |
| Q2 2025 | $1.33 | +639% |
| Q1 2025 | $1.37 | +$1.38 |
| Q4 2024 | $1.36 | +$1.74 |
ACAD's earnings per share have climbed steadily: $2.12 over the past year, up 37% from the year before, and higher year over year for 15 quarters in a row.
ACAD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $342.3M | +23% |
| Q2 2026 | $308M | +16% |
| Q1 2026 | $268.1M | +9.7% |
| Q4 2025 | $284M | +9.4% |
| Q3 2025 | $278.6M | +11% |
| Q2 2025 | $264.6M | +9.3% |
| Q1 2025 | $244.3M | +19% |
| Q4 2024 | $259.6M | +12% |
ACAD's revenue has grown year over year for 16 quarters in a row: $342M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +8.1 points |
| Q2 2026 | 12% | 0 points |
| Q1 2026 | -1.7% | -9.6 points |
| Q4 2025 | 6.1% | -53 points |
| Q3 2025 | 13% | +0.2 points |
| Q2 2025 | 12% | -0.3 points |
| Q1 2025 | 7.9% | +0.5 points |
| Q4 2024 | 59% | +44 points |
ACAD's operating margin was 21% last quarter, up 8.1 points from the same quarter a year ago, near the top of its range since 2019.
ACAD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | -86% |
| Q1 2026 | $28.8M | +42% |
| Q4 2025 | -$52.7M | -232% |
| Q1 2025 | $20.3M | -30% |
| Q4 2024 | $39.9M | -53% |
| Q2 2024 | $25M | +205% |
| Q1 2024 | $29.1M | +$47M |
| Q4 2023 | $85.4M | +$109.2M |
ACAD has burned cash in most quarters: $82M over the past year, down 48% from the year before.
ACAD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +2.6M shares |
| 1 year | +2.8% | +4.8M shares |
| 3 years | +8.8% | +14.2M shares |
| 5 years | +13% | +20.1M shares |
ACAD has 175M diluted shares, up 2.8% from a year ago.
ACAD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.4x | Net Cash |
| Q2 2026 | -3.9x | Net Cash |
| Q1 2026 | -3.0x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.3x | Net Cash |
ACAD has more cash than debt.
ACAD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 18.4 | Oversold |
ACAD's weekly RSI is 35 (neutral) and its Stochastic is 18 (oversold).
ACAD PE vs Healthcare Sector
| Metric | ACAD | Sector median | Relative |
|---|---|---|---|
| PE | 8.6x | 26x | 67% below |
| PE % | 0 | 29 | 29 pts below |
ACAD is trading at 8.6x earnings, a 67% discount to the Healthcare sector's median of 26x.
ACAD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.9 | 8.8% below |
| 20 week MA | $24.4 | 26% below |
| 50 week MA | $23.8 | 24% below |
| 100 week MA | $22.2 | 18% below |
| 200 week MA | $21.6 | 16% below |
ACAD is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
ACAD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.0 | $55.0 | +25% |
| 2021 | $55.0 | $24.3 | -56% |
| 2022 | $24.3 | $15.5 | -36% |
| 2023 | $15.5 | $31.3 | +102% |
| 2024 | $31.3 | $17.0 | -46% |
| 2025 | $17.0 | $27.6 | +63% |
| 2026 YTD | $27.6 | $18.1 | -34% |
ACAD's yearly returns have swung widely, from +102% in 2023 to −56% in 2021. It's down 34% so far in 2026.